Net Worth Advisory Group Cuts Position in Sanofi (NASDAQ:SNY)

Net Worth Advisory Group trimmed its position in shares of Sanofi (NASDAQ:SNY) by 4.0% during the 4th quarter, Holdings Channel reports. The fund owned 4,940 shares of the company’s stock after selling 207 shares during the period. Net Worth Advisory Group’s holdings in Sanofi were worth $238,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Sanofi during the fourth quarter valued at approximately $135,933,000. Jennison Associates LLC raised its holdings in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its position in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after buying an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after buying an additional 664,455 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Trading Down 1.0 %

SNY opened at $58.74 on Wednesday. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The company has a market capitalization of $149.07 billion, a P/E ratio of 23.59, a PEG ratio of 1.01 and a beta of 0.58. The stock’s fifty day moving average is $53.08 and its two-hundred day moving average is $52.78. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.